Literature DB >> 15906230

Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma.

Ronit Lahav1.   

Abstract

Since embryonic development and tumorigenesis share common characteristics, studying the role of genes during development can identify molecules that have similar functions in both processes. C-kit and Endothelin receptor B (EDNRB or ETRB) are crucial for melanocyte development in mice and humans but have different functions. While c-kit is needed for survival throughout development until late stages of differentiation in the skin, EDNRB promotes early expansion and migration while delaying the differentiation of melanocyte precursors. Transformation of normal melanocytes to melanoma cells is often associated with gradual loss of differentiation and the gain of high autonomous capacity to proliferate. In accordance with their different roles, c-kit expression is gradually lost during melanoma transformation, while that of EDNRB is greatly enhanced and can serve as a marker of melanoma progression. Inhibiting EDNRB function with a specific antagonist (BQ788) in human melanoma cell lines results in inhibition of growth often associated with induced differentiation indicating that, during melanoma transformation also, the function of EDNRB is to promote growth. EDNRB function does not seem to be essential in the adult, as BQ788 administration to healthy people does not result in major effects. This is probably why BQ788 can specifically inhibit the growth of xenograft human melanoma tumors in nude mice, in a way resembling spontaneous human melanoma regression and why it could serve as a potential therapeutic agent for melanoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906230     DOI: 10.1387/ijdb.041951rl

Source DB:  PubMed          Journal:  Int J Dev Biol        ISSN: 0214-6282            Impact factor:   2.203


  27 in total

1.  Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.

Authors:  Aurélie Borrull; Bertrand Allard; Anne Wijkhuisen; Amaury Herbet; Patricia Lamourette; Wided Birouk; Denis Leiber; Zahra Tanfin; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud; Philippe Robin
Journal:  MAbs       Date:  2016-07-08       Impact factor: 5.857

Review 2.  Melanocyte receptors: clinical implications and therapeutic relevance.

Authors:  J Andrew Carlson; Gerald P Linette; Andrew Aplin; Bernard Ng; Andrzej Slominski
Journal:  Dermatol Clin       Date:  2007-10       Impact factor: 3.478

Review 3.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

4.  Substance P stimulates endothelin 1 secretion via endothelin-converting enzyme 1 and promotes melanogenesis in human melanocytes.

Authors:  Phil June Park; Tae Ryong Lee; Eun-Gyung Cho
Journal:  J Invest Dermatol       Date:  2014-09-30       Impact factor: 8.551

Review 5.  Role of the endothelin axis and its antagonists in the treatment of cancer.

Authors:  A Bagnato; M Loizidou; B R Pflug; J Curwen; J Growcott
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

6.  Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.

Authors:  Francesca Spinella; Laura Rosanò; Martina Del Duca; Valeriana Di Castro; Maria Rita Nicotra; Pier Giorgio Natali; Anna Bagnato
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

Review 7.  G-protein-coupled receptors and melanoma.

Authors:  Hwa Jin Lee; Brian Wall; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-27       Impact factor: 4.693

8.  Endothelin (ET)-1 and ET-3 promote expression of c-fos and c-jun in human choriocarcinoma via ET(B) receptor-mediated G(i)- and G(q)-pathways and MAP kinase activation.

Authors:  A Rauh; W Windischhofer; A Kovacevic; T DeVaney; E Huber; M Semlitsch; H-J Leis; W Sattler; E Malle
Journal:  Br J Pharmacol       Date:  2008-03-24       Impact factor: 8.739

Review 9.  The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

Authors:  N S Kirkby; P W F Hadoke; A J Bagnall; D J Webb
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

Review 10.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.